









Markets
/
Stocks
/
nasdaq-abcl
/

Abcellera Biologics Inc

ABCL

View Detailed Chart

4.480USD

+0.580+14.87%

Close 07/18, 16:00（ET）Quotes delayed by 15 min

1.34BMarket Cap

LossP/E TTM



Abcellera Biologics Inc

4.480

+0.580+14.87%

Overview Company Financials

Financials

Intraday

30m

Today

+14.87%

5 Days

+11.72%

1 Month

+29.11%

6 Months

+50.84%

Year to Date

+52.90%

1 Year

+46.41%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

9.143

Target Price

134.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

553

Total

Median

Average

Company name

Ratings

Analysts

Abcellera Biologics Inc

ABCL

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(3)

Buy(8)

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Neutral

RSI(14)

66.950

Neutral

STOCH(KDJ)(9,3,3)

58.350

Neutral

ATR(14)

0.349

High Vlolatility

CCI(14)

130.732

Buy

Williams %R

15.493

Overbought

TRIX(12,20)

1.559

Sell

StochRSI(14)

80.916

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.124

Buy

MA10

4.102

Buy

MA20

3.853

Buy

MA50

2.961

Buy

MA100

2.677

Buy

MA200

2.796

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Ticker SymbolABCL

CompanyAbcellera Biologics Inc

CEODr. Carl L.G. Hansen, Ph.D.

Websitehttps://www.abcellera.com/